BR112022025880A2 - Administração de antagonista de cebp-beta e métodos de uso - Google Patents

Administração de antagonista de cebp-beta e métodos de uso

Info

Publication number
BR112022025880A2
BR112022025880A2 BR112022025880A BR112022025880A BR112022025880A2 BR 112022025880 A2 BR112022025880 A2 BR 112022025880A2 BR 112022025880 A BR112022025880 A BR 112022025880A BR 112022025880 A BR112022025880 A BR 112022025880A BR 112022025880 A2 BR112022025880 A2 BR 112022025880A2
Authority
BR
Brazil
Prior art keywords
methods
cebp
antagonist administration
beta
beta antagonist
Prior art date
Application number
BR112022025880A
Other languages
English (en)
Portuguese (pt)
Inventor
Jay Kappel Barry
Merutka Gene
Andrew Rotolo Jimmy
e michel Robert
Susannah Bexon Alice
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of BR112022025880A2 publication Critical patent/BR112022025880A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022025880A 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e métodos de uso BR112022025880A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041991P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
BR112022025880A2 true BR112022025880A2 (pt) 2023-01-10

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025880A BR112022025880A2 (pt) 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e métodos de uso

Country Status (17)

Country Link
US (1) US20230218717A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7880618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027054A (cg-RX-API-DMAC7.html)
CN (1) CN115768458A (cg-RX-API-DMAC7.html)
AU (1) AU2021297172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4168033T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066151T3 (cg-RX-API-DMAC7.html)
FI (1) FI4168033T3 (cg-RX-API-DMAC7.html)
IL (1) IL299104A (cg-RX-API-DMAC7.html)
MX (1) MX2022016478A (cg-RX-API-DMAC7.html)
NZ (1) NZ795026A (cg-RX-API-DMAC7.html)
PT (1) PT4168033T (cg-RX-API-DMAC7.html)
WO (1) WO2021262604A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213167B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119997967A (zh) * 2022-10-07 2025-05-13 智慧疗法有限公司 C/EBP-β拮抗剂和免疫调节剂的使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
EP4694911A2 (en) * 2023-04-13 2026-02-18 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
CA2983030A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
PT3737399T (pt) 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
ES3066151T3 (en) 2026-05-11
EP4168033A4 (en) 2024-06-19
AU2021297172A1 (en) 2023-01-19
KR20230027054A (ko) 2023-02-27
EP4168033B1 (en) 2026-02-25
FI4168033T3 (fi) 2026-04-07
US20230218717A1 (en) 2023-07-13
IL299104A (en) 2023-02-01
PT4168033T (pt) 2026-03-24
JP7880618B2 (ja) 2026-06-26
AU2021297172B2 (en) 2025-01-30
DK4168033T3 (da) 2026-05-11
MX2022016478A (es) 2023-02-01
ZA202213167B (en) 2026-03-25
CA3180559A1 (en) 2021-12-30
EP4168033A2 (en) 2023-04-26
NZ795026A (en) 2026-03-27
JP2023531683A (ja) 2023-07-25
WO2021262604A3 (en) 2022-02-17
WO2021262604A2 (en) 2021-12-30
CN115768458A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
PE20251185A1 (es) Proteinas de union condicionalmente activadas restringidas
PE20251254A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
BR112021017399A2 (pt) Proteína de fusão bifuncional e uso farmacêutico da mesma
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
SI3079715T1 (en) A mixture of peptides
EA202191651A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
CY1124916T1 (el) Υγρο σκευασμα νευροτοξινης σταθεροποιημενο με τρυπτοφανη ή τυροσινη
WO2021222150A3 (en) Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
MY169272A (en) Her2 antibody composition
WO2021262604A3 (en) Administration of cebp-beta antagonist and methods of use
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
EA202192726A1 (ru) Magea1-специфические т-клеточные рецепторы и их использование
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
CL2020003293A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
PE20241584A1 (es) Proteinas que se unen a nkg2d, cd16 y baff-r
WO2023023588A3 (en) Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
BR112021000899A2 (pt) Peptídeos de ligação a il-17a e usos médicos dos mesmos
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
BR112022007776A2 (pt) Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína
BR112022007203A2 (pt) Compostos imunogênicos para tratamento de câncer adrenal
MX2022002277A (es) Metodo para incrementar el conteo de linfocitos mediante el uso de proteina de fusion de interleucina 7 (il-7) en tumores.
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SAPIENCE THERAPEUTICS, INC. (US)